

Medicortex International publishes company presentation

Medicortex International AB (publ) today publishes an updated company presentation. The presentation will be used in meetings with investors and other stakeholders, and is being published so that all market information is available to all shareholders at the same time.

The presentation describes the group following the acquisition of Medicortex Finland Oyj. It covers the need for better diagnostics for traumatic brain injury and concussion, the company's urine-based rapid test ProbTBI® and the saliva-based test in development. It also outlines the planned product timeline, the market, the competitive landscape, the patent portfolio, funding history and the group's holdings as of 30 September 2026.

"We want all shareholders to have the same picture of Medicortex as the investors we meet. The presentation gives a complete overview of where we stand today and the path towards a finished test for brain injury," says Adrian Harel, CEO of Medicortex International AB (publ).

The presentation is attached to this press release and will also be made available on the company's website, medicortex.eu.

Contacts

Adrian Harel, adrian.harel@medicortex.fi, Phone: +358 (0) 400488817
Jesper Yrwing, jesper@nosium.com, Phone: +46 70 860 60 07

About Medicortex International

Medicortex International AB (publ) is the parent company of Medicortex Finland Oyj, a Finnish medical technology company developing non-invasive diagnostic tests for traumatic brain injury. The company has received 8.4 million EUR in funding, including three grants from the U.S. Department of Defense, and holds a strong patent portfolio with 10 patents. The global market for TBI diagnostics is expected to reach 3.3 billion USD by 2029. More information is available at medicortex.fi and medicortex.eu

The share is traded on the NGM Growth Market under the ticker: **MEDFIN**.

The company's mentor is: **Nordic Certified Adviser AB**.

Attachments

**Medicortex International publishes company presentation
2026 10 19 Medicortex International Presentation**